2 Word count: 1,384 words. 3 ABSTRACT Purpose: To determine prognostic factors associated with prolonged survival after metastasectomy for urothelial carcinoma (UC). Materials and Methods: Forty-two patients who underwent resection of metastases of UC with curative intent at 4 different Japanese university hospitals were included. Most of the patients (41/42) underwent systemic chemotherapy before and/or after metastasectomy. Overall survival was analyzed using the Kaplan-Meier method, and the relationship between the clinical characteristics and survival was analyzed using the log-rank test. Results: Details of metastasectomy were as follows: lymph node dissection (n=20), pulmonary resection (n=12), pelvic exenteration (n=3), resection of local recurrence (n=2), resection of subcutaneous metastasis (n=2), liver resection (n=1), and others (n=2). The median overall survival time was 29 months (interquartile range [IQR]:
INTRODUCTION
Systemic chemotherapy is the mainstay of treatment for metastatic urothelial carcinoma (UC). Although initial response rates are 50-70% 1, 2 , these responses are usually transient. Long-term survival is achieved in only a small proportion of patients.
In order to improve the outcome, several investigators have advocated the resection of metastases (so-called "metastasectomy") for surgical consolidation. [3] [4] [5] [6] [7] [8] [9] [10] For example, our group previously reported a median survival of 42 months in 12 patients undergoing complete resection of all detectable metastases, which was significantly longer than that of patients who did not undergo metastasectomy (10 months). 6 However, its role and characteristics associated with long-term survival after metastasectomy remain undetermined.
The aim of this retrospective multi-institutional study was to examine the long-term outcomes and characteristics associated with prolonged survival after metastasectomy of UC. 6 
MATERIALS AND METHODS
Each institutional review board approved the retrospective review and analysis of metastatic UC patients undergoing metastasectomy during the study period.
Between 1989 and 2012, 42 patients with metastatic UC underwent resection of metastasis at 4 different Japanese university hospitals. These surgeries were performed with a curative intent.
Patients undergoing metastasectomy for symptom palliation were not included. Demographic, surgical, pathological, and follow-up data were retrospectively collected from medical charts. During the study period, all therapeutic decisions including the extent of lymph node dissection (LND) at the time of radical cystectomy or nephroureterectomy, indication of neoadjuvant or adjuvant chemotherapy, or the choice of the respective chemotherapy regimens at the development of metastasis, were left to the discretion of each attending doctor on the basis of individual disease characteristics and patients' requests. Regarding the indication of metastasectomy, we considered metastasectomy when patients had metastasis in a single organ with a small number of metastases, a good performance status, and showed a favorable response to chemotherapy, although we did not have strict prospective criteria. In a situation contrasting to the above-mentioned one (e.g., more than five lung metastases, several organ metastases), we considered second-line chemotherapy. Generally, the disease status was re-evaluated with a chest X-ray or chest CT scan and CT scan of the abdomen and pelvis every 3-6 months. In patients receiving systemic chemotherapy, tumor responses were assessed every two or three cycles by CT scan, although confirmation was not always carried out. Bone scans were conducted if symptoms were present.
Overall survival was analyzed from the initiation of treatment for metastatic UC or the time of metastasectomy until death or the last follow-up according to the Kaplan-Meier method, using the log-rank test to assess the significance of differences. Table 1 shows the patients' characteristics. The median patient age at the start of treatment for metastatic disease was 67.5 years (range: 36-80). The primary tumor site was the bladder in 21 patients, upper urinary tract in 18 patients, and both in 3 patients.
RESULTS
In this cohort, 39 patients had metastatic disease involving a single organ, while 3 had disease involving double organs at the presentation of metastases. The number of metastases was one in 23 patients, 2 or more in 14 patients, and uncountable due to aggregated metastatic LNs in 5 patients. Thirty-six patients developed metastasis after resection of the primary site, while 6 already demonstrated metastases at the diagnosis of primary cancer. In the present study, of the 8 patients with disease in the regional LNs, five patients developed regional LN recurrence after nephroureterectomy (pathological node status at nephroureterectomy, pN0: n=1, pN+: n=1, pNx: n=3) and 1 after radical cystectomy (pathological node status at radical cystectomy, pN0: n=1).
Of the remaining two patients, one had aggregated LN metastasis at the initial presentation and underwent LND at the time of nephroureterectomy after systemic chemotherapy with a complete response of lung metastasis, and the other patient underwent LND after salvage systemic chemotherapy, although LND had been discontinued at the time of nephroureterectomy after induction chemotherapy. The median disease-free interval between surgical resection of the primary cancer and the 9 development of metastasis was 16 months (range: 0-103). All but one patient received systemic chemotherapy, and the dominant treatment course was "metastasectomy after systemic chemotherapy" (n=34). Table 2 shows a summary of chemotherapy regimens used in the present cohort. In the present cohort, MVAC/ MEC/ GC regimens were used as induction chemotherapy in most of the patients.
Paclitaxel or docetaxel-including regimens were performed in 21 patients as salvage therapy after induction chemotherapy, or for disease recurrence after cisplatin-based neoadjuvant or adjuvant chemotherapy. Finally, during the treatment course, 23 patients received at least two different chemotherapy regimens. There was no operative mortality. Seven patients underwent repeat metastasectomy. Figure 1c , log-rank test p = 0.0296).
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DISCUSSION
In 1982, Cowles and colleagues were the fist group to report the surgical outcomes in patients with pulmonary metastasis of UC. 7 They reported a median 5-year OS rate was observed. 8 In the present study, we observed a similar result of a median OS of 26 months after metastasectomy. Our observations further support the possibility of long-term cancer control after metastasectomy.
The appropriate selection of patients for metastasectomy is essential if this approach is to be considered for general use. As described in Methods, in the present cohort, metastasectomy was considered in patients with limited single organ metastasis or in those with residual disease after a major response to systemic chemotherapy.
Regarding the indication of metastasectomy, investigators described a similar opinion in their studies. Siefker-Radtke et al. indicated that their strategy was to consider metastasectomy in patients who responded to chemotherapy and showed recurrence at the initial or a single metastatic site, who had a tumor considered surgically resectable with clear margins, and showed a period of disease stability with no evidence of rapid progression (3-month observation interval between chemotherapy and metastasectomy), although these criteria were used as a general guideline and not an absolute requirement. 3 Lehmann stated that this therapeutic approach remains highly investigational and should only be offered to patients with relapse at a single site or at the initial site following chemotherapy, in whom complete resection of all detectable masses is feasible. 8 Svatek Taken together with these observations, clinicians should carefully select patients, considering the "stability", "spread", and "resectability" of metastatic disease.
There was a negative report from Otto et al. in which the median survival time was 7 months after the surgical removal of metastases from bladder cancer refractory to systemic therapy. 12
As described above, of the 8 patients with the disease in the regional lymph nodes, five patients developed regional LN recurrence after nephroureterectomy (pathological node status at nephroureterectomy, pN0: n=1, pN+: n=1, pNx: n=3) and 1 after radical cystectomy (pathological node status at radical cystectomy, pN0: n=1). The extended LND approach at the time of primary surgery may prevent such recurrence. 13, 14 Our study was limited by the small sample size, heterogeneous cohort, retrospective nature, and diversity of treatment strategies. For example, our cohort included metastatic urothelial carcinomas derived from bladder and/or upper urinary tract together, which might have different biological behaviors regardless of the same histology. In addition, the timing of metastasectomy was not considered for study Results of univariate analysis of prognostic significance after metastasectomy.
